|| Checking for direct PDF access through Ovid
In patients with severe chronic neutropenia, filgrastim treatment has successfully increased neutrophil counts and reduced the incidence of infections and need for antibacterial drugs. This has resulted in improvements in patients' quality of life. Preliminary evidence suggests that the benefits of filgrastim are maintained long-term without substantial adverse effects.Further data are required to determine the effect of filgrastim on the risk of malignant transformation of congenital neutropenia. If the favourable long-term adverse effect profile is confirmed, filgrastim is likely to become a treatment of choice for patients with these rare primary neutropenic conditions.